Nykode Posts $7.2 Million Q2 Loss as Abili-T Advances

Nykode Therapeutics AS (OTC: VACBF) reported a net loss of $7.2 million for the second quarter of 2026 while advancing its Abili-T trial and pointing to positive industry data supporting its cancer vaccine platform.

Nykode Therapeutics AS (OTC: VACBF) told investors on its second-quarter call that it lost $7.2 million in the three months to the end of the period, a figure that says as much about how the Norwegian immunotherapy developer is managing its spending as it does about the state of its pipeline. For a clinical-stage company with no marketed product, the loss line is effectively the burn line, and $7.2 million is a modest quarterly number by the standards of the sector.

Management framed the quarter around two things: continued progress on the Abili-T trial and a wider run of positive industry data that, in its telling, validates the therapeutic cancer vaccine approach the company has built its platform around. Those are the two variables that matter for a business at this stage. One is execution the company controls. The other is sentiment it does not.

What a $7.2 Million Quarter Buys

Clinical-stage biotechs are valued on runway and readouts, and the two are joined at the hip. Every quarter of spending is a quarter closer to a data point that either re-rates the equity or forces a financing on unfavourable terms. A $7.2 million quarterly loss is the kind of number that suggests a company running trials with discipline rather than one throwing capital at parallel programs.

The arithmetic investors will run is straightforward: at a steady $7.2 million per quarter, annualised spending would be roughly $28.8 million — an illustrative extrapolation, not a company forecast, and one that assumes no acceleration in trial costs as enrolment builds. Trial spending rarely stays flat. Costs typically step up as patient numbers grow and as sites multiply across geographies, then fall away once enrolment closes and the study moves into follow-up.

That is the tension in any read of this quarter. A low loss is reassuring on solvency and unhelpful on urgency. The question for holders is not whether Nykode can control costs — the number suggests it can — but whether the pace of spending is consistent with getting Abili-T to a readout before the balance sheet needs topping up again.

Why Abili-T Carries the Story

Abili-T is the program management chose to lead with, and in a single-asset-dominated narrative that makes it the swing factor for the equity. Nykode's platform is built on directing immune responses to specific antigens, and a therapeutic cancer vaccine only proves its worth when a controlled trial shows the immune response translates into a clinical benefit patients can feel.

The company's reference to supportive industry data is worth reading carefully. Therapeutic cancer vaccines spent the better part of two decades as a graveyard for capital, with immunogenicity that looked convincing in the lab and efficacy that repeatedly failed to show up in randomised studies. The renewed interest across the field, driven by newer platforms and better antigen selection, has changed the funding environment for companies in this space. Nykode is explicitly positioning itself inside that shift.

But borrowed credibility from a peer's data cuts both ways. If a competitor produces a clean readout, the whole cohort tends to re-rate. If one produces a miss, the cohort takes the hit regardless of the mechanism differences management will be quick to explain. Investors in small-cap platform biotech are, whether they like it or not, holding a sector position as well as a company position.

The Liquidity Problem With VACBF

VACBF is the over-the-counter line for a company whose primary listing sits in Oslo. That distinction matters more than most US investors appreciate. Price discovery happens on the home exchange, and the OTC quote is a follower — often thinly traded, frequently stale between updates, and subject to currency translation on top of the underlying move.

VACBF is the over-the-counter line for a company whose primary listing sits in Oslo.

Anyone building a position through the American ticker is therefore accepting execution risk that has nothing to do with Nykode's science. Wide bid-ask spreads and low volume can make an orderly exit difficult on exactly the days when investors most want one: the morning after a trial readout, good or bad. The GuruFocus account of the earnings call frames the quarter as strategic advance paired with financial discipline, which is a fair summary of a company doing the unglamorous work between catalysts.

A Quiet Tape for a Quiet Quarter

The results landed in an unremarkable session for the broad market. As of 15:21 GMT on 26 August 2026, the S&P 500 tracker (SPY) was at $765.87, down 0.01% against a previous close of $765.91, with a day range of $764.68 to $766.96. The Nasdaq 100 proxy (QQQ) sat at $710.28, off 0.06% from $710.72, and the Dow 30 tracker (DIA) was at $533.99, down 0.23% from $535.24.

Flat benchmarks mean nothing was pulling small-cap biotech in either direction on macro grounds. Whatever move VACBF makes on the back of this print is company-specific, which is how it should be for a name whose valuation rests entirely on a single clinical hypothesis.

What Determines the Next Re-Rating

Three things will decide how this equity trades from here, and only one of them showed up in the quarterly numbers.

Abili-T enrolment and timing. Any firm guidance on when the trial completes recruitment and when data is expected is the single most valuable disclosure the company can make.
The burn trajectory. Whether $7.2 million is a floor, a ceiling or a steady state determines how long the company can operate before returning to the market for capital.
Peer readouts. Data from other therapeutic cancer vaccine developers will move sentiment on Nykode regardless of what Nykode itself reports.

None of that is knowable from a single quarter's loss statement. What the $7.2 million figure does establish is that the company is not spending recklessly while it waits. For a clinical-stage developer in a field that has burned a lot of capital before finding traction, that restraint is the minimum requirement — not the investment case.

Key facts

Q2 2026 net loss: $7.2 million
Ticker: VACBF (OTC), Norwegian immunotherapy developer
Lead clinical program: Abili-T trial, advancing per management
Market backdrop: S&P 500 tracker SPY at $765.87, -0.01%, as of 15:21 GMT 26 Aug 2026

Frequently asked questions

How much did Nykode Therapeutics lose in the second quarter of 2026?

Nykode Therapeutics reported a net loss of $7.2 million for the second quarter of 2026. For a clinical-stage biotechnology company with no approved product generating revenue, the net loss figure effectively represents the cash burn for the period, and $7.2 million is a comparatively modest quarterly figure within the sector.

What is the Abili-T trial?

Abili-T is the clinical trial Nykode Therapeutics highlighted as advancing during its second-quarter 2026 earnings call. It is the lead program management pointed to when describing strategic progress, making it the principal near-term catalyst for a company whose valuation depends on clinical results rather than product sales.

Where does Nykode Therapeutics trade?

Nykode trades in the United States under the over-the-counter ticker VACBF. Its primary listing is in Oslo, meaning the OTC line follows price discovery on the home exchange. That structure can produce thin volume, wider bid-ask spreads and currency translation effects for American investors.

What is a therapeutic cancer vaccine?

A therapeutic cancer vaccine is designed to treat existing disease rather than prevent it, by training a patient's immune system to recognise and attack tumour cells displaying specific antigens. The field struggled for years to convert strong laboratory immune responses into measurable clinical benefit in randomised trials.

Why does Nykode reference industry data from other companies?

Management cited positive industry data as support for its cancer vaccine platform. In a field where the underlying scientific approach was long questioned, successful readouts from peer companies help validate the mechanism and improve the financing environment for every developer working on similar platforms.

What was the broader market doing when the results were reported?

Markets were essentially flat. As of 15:21 GMT on 26 August 2026, the S&P 500 tracker SPY stood at $765.87, down 0.01%; the Nasdaq 100 proxy QQQ was at $710.28, down 0.06%; and the Dow 30 tracker DIA was at $533.99, down 0.23%.

Sources

Nykode Therapeutics AS (VACBF) (Q2 2026) Earnings Call Highlights: Strategic Advances and ... — GuruFocus

Photo: Gustavo Fring · Pexels Licence — source